Rutgers University-New Brunswick has spun out Infinity Biologix with backing from Viking Global Investors to manage the distribution of a saliva-based coronavirus test.

Infinity Biologix, a US-based coronavirus saliva test developer spun out of Rutgers University-New Brunswick, has launched with an initial $44.4m from investors including hedge fund Viking Global Investors, New Jersey Biz reported on Wednesday. Spun out from the university’s RUCDR Infinite Biologics lab, Infinity Biologix has received emergency-use authorisation in the US for a coronavirus…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.